Physician profile
Rosemarie Y Ingleton
NPI 1366414567
$26,686.22
in general payments reported to CMS, 2019-2025
25 companies · $564 in 2025
The $564 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,040 · 2020: $433 · 2021: $22K · 2022: $783 · 2023: $1,414 · 2024: $227 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,187 · Education: $18.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,187.32 |
| Education | $18.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $20,627.96 | 2021 | |
| Allergan, INC. | $1,425.57 | 2019-2022 | |
| Abbvie INC. | $1,143.31 | 2021-2025 | |
| Galderma Laboratories, L.P. | $700.06 | 2019-2025 | Twyneo, Aklief, Epsolay |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $384.95 | 2019-2025 | Targretin, Jublia, Cabtreo |
| Amgen INC. | $344.62 | 2021-2023 | Otezla |
| Pfizer INC. | $287.64 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $249.35 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $237.88 | 2021-2023 | Dupixent |
| Merz North America, INC. | $166.75 | 2023-2025 | Xeomin |
| Genzyme Corporation | $163.16 | 2022-2023 | |
| Incyte Corporation | $153.32 | 2021-2024 | Opzelura |
| Almirall LLC | $147.64 | 2019-2023 | Seysara, Klisyri |
| Celgene Corporation | $147.55 | 2019 | |
| Leo Pharma INC. | $123.15 | 2021-2023 | Adbry |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $80.49 | 2019-2022 | |
| Janssen Biotech, INC. | $68.96 | 2020-2021 | |
| Lilly USA, LLC | $46.68 | 2023 | Olumiant, Taltz |
| Vyne Pharmaceuticals INC. | $42.59 | 2021 | |
| Mission Pharmacal Company | $29.56 | 2019-2021 | |
| Promius Pharma LLC | $27.87 | 2019 | |
| Journey Medical Corporation | $23.10 | 2019-2020 | |
| Aclaris Therapeutics, INC. | $22.94 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $21.38 | 2025 | |
| Mayne Pharma Commercial LLC | $19.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$31,544.42 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosemarie Ingleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.